230 related articles for article (PubMed ID: 20189175)
1. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes.
Vergès B
Atherosclerosis; 2010 Aug; 211(2):353-60. PubMed ID: 20189175
[TBL] [Abstract][Full Text] [Related]
2. Regulation of plasma triglycerides in insulin resistance and diabetes.
Ginsberg HN; Zhang YL; Hernandez-Ono A
Arch Med Res; 2005; 36(3):232-40. PubMed ID: 15925013
[TBL] [Abstract][Full Text] [Related]
3. Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats.
Qin B; Anderson RA; Kuzuya T; Kitaura Y; Shimomura Y
Atherosclerosis; 2012 Jun; 222(2):409-16. PubMed ID: 22546076
[TBL] [Abstract][Full Text] [Related]
4. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.
Julius U
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):246-50. PubMed ID: 12951628
[TBL] [Abstract][Full Text] [Related]
5. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B
Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160
[TBL] [Abstract][Full Text] [Related]
6. Lipid and lipoprotein dysregulation in insulin resistant states.
Avramoglu RK; Basciano H; Adeli K
Clin Chim Acta; 2006 Jun; 368(1-2):1-19. PubMed ID: 16480697
[TBL] [Abstract][Full Text] [Related]
7. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
8. Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α.
Lucero D; Miksztowicz V; Macri V; López GH; Friedman S; Berg G; Zago V; Schreier L
Clin Investig Arterioscler; 2015; 27(4):167-74. PubMed ID: 25796423
[TBL] [Abstract][Full Text] [Related]
9. SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes.
Li X; Li Y; Yang W; Xiao C; Fu S; Deng Q; Ding H; Wang Z; Liu G; Li X
J Steroid Biochem Mol Biol; 2014 Sep; 143():174-82. PubMed ID: 24565561
[TBL] [Abstract][Full Text] [Related]
10. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling.
Costandi J; Melone M; Zhao A; Rashid S
Circ Res; 2011 Mar; 108(6):727-42. PubMed ID: 21293001
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
[TBL] [Abstract][Full Text] [Related]
12. Diabetic dyslipidaemia: from basic research to clinical practice.
Taskinen MR
Diabetologia; 2003 Jun; 46(6):733-49. PubMed ID: 12774165
[TBL] [Abstract][Full Text] [Related]
13. Secretion of atherogenic risk factor apolipoprotein B-100 is increased by a potential mechanism of JNK/PKC-mediated insulin resistance in liver cells.
Jin UH; Kang YJ; Chang YC; Kim CH
J Cell Biochem; 2008 Feb; 103(3):908-19. PubMed ID: 17647275
[TBL] [Abstract][Full Text] [Related]
14. Increased binding of LDL and VLDL to apo B,E receptors of hepatic plasma membrane of rats treated with Fibernat.
Venkatesan N; Devaraj SN; Devaraj H
Eur J Nutr; 2003 Oct; 42(5):262-71. PubMed ID: 14569407
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes.
Bach-Ngohou K; Ouguerram K; Nazih H; Maugère P; Ripolles-Piquer B; Zaïr Y; Frénais R; Krempf M; Bard JM
Int J Obes Relat Metab Disord; 2002 Nov; 26(11):1451-8. PubMed ID: 12439646
[TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
Ouguerram K; Magot T; Zaïr Y; Marchini JS; Charbonnel B; Laouenan H; Krempf M
J Pharmacol Exp Ther; 2003 Jul; 306(1):332-7. PubMed ID: 12684543
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.
VerHague MA; Cheng D; Weinberg RB; Shelness GS
Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2501-8. PubMed ID: 24030551
[TBL] [Abstract][Full Text] [Related]
18. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease.
Meshkani R; Adeli K
Clin Biochem; 2009 Sep; 42(13-14):1331-46. PubMed ID: 19501581
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling.
Qin B; Anderson RA; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2008 May; 294(5):G1120-9. PubMed ID: 18372392
[TBL] [Abstract][Full Text] [Related]
20. Impaired response of VLDL lipid and apoB secretion to endotoxin in the fasted rat liver.
Aspichueta P; Pérez-Agote B; Pérez S; Ochoa B; Fresnedo O
J Endotoxin Res; 2006; 12(3):181-92. PubMed ID: 16719989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
